posted on 2002-06-04, 00:00authored byZhi-Liang Wei, Sukumar Sakamuri, Pavel A. Petukhov, Clifford George, Nancy E. Lewin, Peter M. Blumberg, Alan P. Kozikowski
Both (2S,5R,6R)- and (2S,5R,6S)-6-hydroxy-8-(1-decynyl)benzolactam-V8 were designed and synthesized as PKC modulators. Biological assays
reveal the (6R)-ligand to be 20-fold more potent than its (6S)-counterpart in binding to PKCα.